Al-Dawaa Medical Services Company (4163.SR)
SAR 79.0
(1.67%)
SAR 79.0
(1.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 830.43 Million SAR | 14.38% |
| 2022 | 784.25 Million SAR | 22.78% |
| 2021 | 659.13 Million SAR | -15.68% |
| 2020 | 627.43 Million SAR | 58.08% |
| 2019 | 447.31 Million SAR | 3.72% |
| 2018 | 431.26 Million SAR | 26.77% |
| 2017 | 340.2 Million SAR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 223.03 Million SAR | 4.06% |
| 2024 Q2 | 227.99 Million SAR | 2.22% |
| 2023 Q2 | 215.97 Million SAR | 5.98% |
| 2023 Q1 | 203.8 Million SAR | -0.4% |
| 2023 FY | - SAR | 14.38% |
| 2023 Q4 | 221.25 Million SAR | 12.7% |
| 2023 Q3 | 196.32 Million SAR | -9.1% |
| 2022 Q4 | 204.61 Million SAR | 19.95% |
| 2022 Q3 | 170.57 Million SAR | -7.58% |
| 2022 Q2 | 184.57 Million SAR | 7.11% |
| 2022 Q1 | 172.32 Million SAR | 14.54% |
| 2022 FY | - SAR | 22.78% |
| 2021 Q3 | 136.67 Million SAR | -11.4% |
| 2021 Q2 | 154.26 Million SAR | -0.41% |
| 2021 Q4 | 150.45 Million SAR | 10.08% |
| 2021 FY | - SAR | -15.68% |
| 2021 Q1 | 154.88 Million SAR | 30.97% |
| 2020 Q2 | 168.31 Million SAR | 13.56% |
| 2020 FY | - SAR | 58.08% |
| 2020 Q4 | 118.26 Million SAR | 0.0% |
| 2020 Q3 | 118.26 Million SAR | -29.74% |
| 2020 Q1 | 148.22 Million SAR | 0.0% |
| 2019 FY | - SAR | 3.72% |
| 2018 FY | - SAR | 26.77% |
| 2017 FY | - SAR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 85.13 Million SAR | -875.411% |
| Nahdi Medical Company | 1.64 Billion SAR | 49.476% |
| Al-Razi Medical Co. | 5.64 Million SAR | -14598.09% |
| Almujtama Alraida Medical Co. | 19.53 Million SAR | -4151.462% |